New care model aims to speed up mental health help for teens
NCT ID NCT02836080
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new way of delivering mental health and addiction services to youth aged 14-17. Instead of standard hospital outpatient care, an integrated team offers rapid access to various services like therapy, peer support, and primary care in a youth-friendly setting. Researchers will compare this approach to usual treatment to see if it improves functioning, reduces substance use, and increases satisfaction.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Integrated Collaborative Care Team (ICCT) model
- What this could lead to
- If successful, this could provide a more effective and youth-friendly way to deliver mental health and addiction services, reducing wait times and improving outcomes.
- What could go wrong
- This is a pragmatic trial comparing a new service model to usual care; results may vary by site and population, and the model may not be easily scaled or sustained.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
247 people
The number who actually took part.
- Started
-
Sep 2016
- Expected to finish
-
Apr 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
14 to 18 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Provision of informed consent 2. Aged 14 - 17 years 11 months 3. New referrals to one of the four participating hospitals for out-patient MHA services 4. Among the population regularly accepted for out-patient services at that hospital Exclusion Criteria: 1. Referral for specialty forensic or firesetting treatment 2. Moderate to severe intellectual disability or autism without MHA problems 3. Primary diagnosis of an eating disorder 4. Active psychosis or imminent risk of self-harm requiring immediate intervention 5. Inability to read and write English or to consent to the study
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Addiction are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health (CAMH)
Toronto, Ontario, M6J 1H4, Canada
-
Michael Garron Hospital
Toronto, Ontario, M4C 3E7, Canada
-
North York General Hospital
Toronto, Ontario, M2K 1E1, Canada
-
Sunnybrook Hospital
Toronto, Ontario, M4N 3M5, Canada
-
The Hospital for Sick Children
Toronto, Ontario, M5G 1X8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can schools catch teen mental health struggles before they escalate?
- Your mood may be steering your choices: scientists track emotions to predict behavior
- A new study mines health data to spot painkiller dependence early
- Can flexible mental health care keep people out of the hospital?
- Can a 6,000-Person study unlock personalized depression care for asians?
- A window into young hearts: new biomarkers may spot antipsychotic side effects early